Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment

Table 3

SD-CCRT/BioRT characteristics of patients received.

Characteristic	SD-CCRT (𝑛=116)	BioRT (𝑛=54)	𝑃 value
Cisplatin cumulative dose (mg/m^2)
≧200	75 (64.7%)
<200	41 (35.3%)
CFHx cycles
2	98 (84.5%)
1	18 (15.5%)
Cetuximab cycles
≧6		49 (90.7%)
5		4 (7.4%)
4		1 (1.9%)
Median RT dose (Gy)	70 (64∼74)	70 (64∼72)	0.268
Median RT interval (days)	46.0 (35∼79)	46.5 (34∼62)	0.078